Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Vestibular Neuronitis

ClinicalTrials.gov lists 33 trials for Vestibular Neuronitis or a narrower condition beneath it. Otolith Labs has the most among industry and government lead sponsors, with 2.

MeSH D020338 Otorhinolaryngologic Diseases C09 C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 2 Phase 3 Phase 3 2 Phase 4 Phase 4 2 Not applicable Not applicable 18 Observational Observational 7 Phase 1 Phase 1 1 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 2 Phase 3 Phase 3 2 Phase 4 Phase 4 2 Not applicable Not applicable 18 Observational Observational 7

Trials per phase

33 of the 33 trials are tagged with Vestibular Neuronitis itself; the rest are tagged with a narrower condition beneath it.

Get the Vestibular Neuronitis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Vestibular Neuronitis trials start? (18)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 7

2000: 1 trials (Not applicable 1) 2001: 1 trials (Phase 1/2 1) 2005: 1 trials (Phase 2 1) 2007: 1 trials (Observational 1) 2010: 1 trials (Phase 1 1) 2011: 1 trials (Not applicable 1) 2013: 2 trials (Phase 4 1, Phase 3 1) 2014: 3 trials (Not applicable 2, Phase 3 1) 2015: 3 trials (Observational 1, Not applicable 1, Phase 4 1) 2017: 2 trials (Not applicable 1, Phase 2 1) 2018: 1 trials (Observational 1) 2019: 4 trials (Observational 1, Not applicable 3) 2020: 1 trials (Observational 1) 2021: 7 trials (Observational 1, Not applicable 6) 2022: 1 trials (Observational 1) 2024: 1 trials (Not applicable 1) 2025: 1 trials (Not applicable 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 1
2025 1
2024 1
2022 1
2021 7
2020 1
2019 4
2018 1
2017 2
2015 3

No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Vestibular Neuronitis trials in? (7)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1
Phase 1/2 1
Phase 2 2
Phase 3 2
Phase 4 2
Not applicable 18
Observational 7

How many Vestibular Neuronitis trials are recruiting? (6)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 1
Recruiting 2
Enrolling by invitation 1
Completed 17
Terminated 3

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Vestibular Neuronitis trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Otolith Labs 2

Which drugs are being tested for Vestibular Neuronitis? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Prednisone 2
Betamethasone 1
PREDNISOLONE 1
Corticosteroid 1

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Ginkgo biloba & Methylprednisolone 1
98% dehydrated alcohol 1
Control (placebo) group 1
Corticosteroids 1
Renexin (cilostazol 100mg + gingko biloba extract 80 mg) 1

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which publications cover Vestibular Neuronitis? (35)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Acute unilateral vestibulopathy and corticosteroid treatment - A randomized placebo-controlled double-blind trial. Journal of vestibular research : equilibrium & orientation 2025 Yes
The co-existence of peripheral and vestibular neuropathy in diabetes: a cross-sectional study. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2024 Yes
Vestibular function testing in the 21st century: video head impulse test, vestibular evoked myogenic potential, video nystagmography; which tests will provide answers? Current opinion in neurology 2022 Yes
Etiologic distribution of dizziness and vertigo in a referral-based dizziness clinic in South Korea. Journal of neurology 2020 Yes
Efficacy of Vestibular Rehabilitation Following Acute Vestibular Neuritis: A Randomized Controlled Trial. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2020 Yes

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages